Table 5.

Active* clinical trials including selinexor (where recruitment is ongoing or anticipated)

Trial	Phase	N	Inclusion	Intervention	Primary endpoint	Status
NDMM
NCT04717700	2	100	Transplant ineligible	Selinexor + V/R (alternating) + dexversus VRD light	ORR	Recruiting
NCT04782687	2	100	Transplant ineligible	Selinexor + DRd	CR, sCR, safety	Recruiting
NDMM + RRMM
NCT02343042 (STOMP)	1b/2	518	Specific to treatment arm	Selinexor + dexamethasone with: P, V, R, PV, Daratumumab, K, R, ixazomib, P + elotuzumab, belamaf, P + daratumumab	Safety, duration of response, ≥ MR	Recruiting
RRMM
NCT04891744	1/2	48	≥ 1 prior line	Selinexor + Td	ORR	NYR (start: July 2021)
NCT04925193	2	20	≥ 1 prior line	Selinexor + Pd,or Selinexor + Kd,or Selinexor + daratumumab + dex	ORR	Recruiting
NCT05170789	2	18	≥ 1 prior line	Selinexor + elotuzumab + dexamethasone	ORR	NYR (start: January 2022)
NCT04877275	2	50	≥ 1 prior line	Selinexor + doxorubicin + dex,or Selinexor + cyclophosphamide + dex	ORR	Recruiting
NCT04941937	2	90	≥ 1 prior line	Selinexor + Td or Selinexor + Rd or Selinexor + Pd	ORR	Recruiting
NCT03732703 (MyDRUG)	1/2	228	1–3 prior lines with early relapse	Selinexor + ixazomib + Pd versus7 other treatment arms	ORR	Recruiting
NCT02199665	1	100	≥ 2 prior lines	Selinexor + Kd	MTD	Recruiting
NCT03944057 (MARCH)	2	82	IMID and PI refractory	Selinexor + dexamethasone	ORR	Recruiting
NCT04661137	2b	96	K or P refractory	Selinexor + Pd,or Selinexor + Kd,or Selinexor + daratumumab + dex (exploratory)	ORR	Recruiting
NCT04756401	2	52	1–3 prior lines, high riska	Selinexor + Kd + daratumumab	MRD(-)	NYR (start: August 2022)
NCT04843579	2	26	1–4 prior lines	Selinexor + Pd + clarithromycin	ORR	Recruiting
NCT04414475	2b	134	> 1–5 prior lines (based on treatment arm)	Selinexor + dex (varying doses),versus Selinexor + Vd	ORR	Recruiting
NCT05028348	3	280	1–4 prior lines	Selinexor + Pdversus Elotuzumab + Pd	PFS	NYR (start: March 2022)
NCT04939142	3	150	1–3 prior lines	Selinexor + Vd,versus Vd	PFS	Recruiting
NCT04519476	Pilot	22	≥ 3 prior lines	Selinexor + lenalidomide + methylprednisolone	ORR, CBR	Recruiting
NCT04764942	1/2	81	≥ 2–3 prior lines (based on treatment arm), PI/IMID refractory	Selinexor + Pd ± carfilzomib	MTD, ORR	Recruiting
NCT05201118	1	30	≥ 3 prior lines, extramedullary disease,	Selinexor + CT103A (anti-BCMA CART)	PFS, ORR, DOR	NYR (start: February 2022)
NCT03589222	2	62	≥ 3 prior lines	Selinexor + Vd + daratumumab	ORR	Recruiting

Bold data: Disease status at trial inclusion

Abbreviations: NDMM, newly diagnosed multiple myeloma; RRMM, relapsed refractory multiple myeloma; ORR, overall response rate being ≥ partial response; CBR, clinical benefit rate; CR, complete response rate; sCR, stringent complete response; PFS, progression-free survival; DOR, duration of response; MTD, maximum tolerated dose; MR, minimal response; MRD, minimal residual disease; NYR, not yet recruiting; V, bortezomib; R, lenalidomide; DRD, daratumumab + lenalidomide + dexamethasone; BCMA, B-cell maturation antigen; CART, chimeric antigen receptor T-cell; Pd, pomalidomide + dexamethasone; Kd, carfilzomib + dexamethasone; Vd, bortezomib + dexamethasone; P, pomalidomide; Td, thalidomide + dexamethasone; Rd, lenalidomide + dexamethasone; IMID, immunomodulatory drug; PI, proteosome inhibitor

^aHigh-risk MM defined as at least one of del1p, gain1q (≥ 3 copies), del17p, t(4;14), t(14;16), t(14;20), LDH above upper limit of normal, extramedullary disease, ISS stage 3 at relapse, ≥ 5% circulating plasma cells at relapse, high-risk gene expression profiling, relapse < 18 months on upfront transplant-ineligible regimen, and < 36 months post-ASCT on maintenance

^*This table was up to date as of at the date of manuscript submission